Protagenic Therapeutics Net Income Applicable To Common Shares Over Time
| PTIX Stock | USD 0.50 0.02 3.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Protagenic Therapeutics Performance and Protagenic Therapeutics Correlation. Protagenic |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Return On Assets (0.90) | Return On Equity (2.06) |
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Protagenic Therapeutics and related stocks such as Sino Biopharmaceutical, Zivo Bioscience, and Cyteir Therapeutics Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELDN | (941 K) | (941 K) | (941 K) | (941 K) | (941 K) | (941 K) | (941 K) | (10.8 M) | (14.1 M) | (16 M) | (22.8 M) | (34.5 M) | (34.5 M) | (31.1 M) | (29.5 M) |
| RZLT | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (11.4 M) | (20.9 M) | (23.7 M) | (29.9 M) | (32.7 M) | (20.3 M) | (20.9 M) | (41.1 M) | (51.8 M) | (46.6 M) | (44.3 M) |
| TPST | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (19.2 M) | (28.3 M) | (28.3 M) | (25.5 M) | (26.7 M) |
| AVTE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (9.8 M) | (23 M) | (23 M) | (20.7 M) | (19.7 M) |
| ADAG | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (16.7 M) | (42.6 M) | (73.2 M) | (73.2 M) | (65.9 M) | (62.6 M) |
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (16.2 M) | (31.2 M) | (28.1 M) | (29.5 M) |
| ANTX | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (14.6 M) | (28.1 M) | (42.8 M) | (38.5 M) | (40.4 M) |
Protagenic Therapeutics and related stocks such as Sino Biopharmaceutical, Zivo Bioscience, and Cyteir Therapeutics Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Protagenic Therapeutics | PTIX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.5
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.